Pharmacogenomics: challenges and opportunities in therapeutic implementationEdited by Yui-Wing FrancisLam and LarisaCavallari. 2013. 510 pp. Hardcover, price £60.99. ISBN 978--0-12-391918-2

The Costs and Benefits of Animal Experiments: An Evaluation with Bias. By Andrew Knight. Palgrave Macmillan: Basingstoke, Hampshire, UK, 2011; Hardcover, 272 pp; ISBN 978-0-230-57686-5; Paperback, ISBN: 978-0-230-57687-2.

The book is part of the Palgrave Macmillan Animal Ethics Series which was developed with the publisher and the Oxford Centre for Animal Ethics. Andrew Knight is a Fellow of the latter. The Centre "aims to demonstrate rigorous intellectual enquiry and the highest standard of scholarship" (p. xv), and the series aims to satisfy the growing appetite for literature in the field. Knight presents a w...

Pharmacogenomics: challenges and opportunities.

The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The seque...

Geometry of Crystallographic Groups. By Andrzej Szczepanski. World Scientific, 2012. Pp. 208. Price (hardcover) GBP 51.00. ISBN 978-981-4412-25-4

International Tables for Crystallography, Volume A, Space-group symmetry. 6th edition. Edited by Mois I. Aroyo. Wiley, 2016. Pp. xxi + 873. Price GBP 295.00, EUR 354.00 (hardcover). ISBN 978-0-470-97423-0.

Volume A of International Tables for Crystallography approaches its 100th birthday. In fact, although it first appeared under this title only in 1935, its predecessor is the book by Wyckoff (1922), which already contained lists of general and special equivalent positions (later to be called Wyckoff positions) and, in its second edition (Wyckoff, 1930), also three-dimensional drawings of the sym...

Pharmacogenomics of osteoporosis: opportunities and challenges.

The genetics of osteoporosis can be considered in two broad areas: disease susceptibility and drug activity. While the former has been studied, the latter is still largely untouched. Pharmacogenomics is the utilization of genetic information to predict outcome of drug treatment, with respect to both beneficial and adverse effects. The pharmacotherapy of osteoporosis is characterized by variabil...